Michael F. Para
Ohio State University
Columbus
USA
Name/email consistency: high
- Phase I/II trial of the anti-HIV activity of mifepristone in HIV-infected subjects ACTG 5200. Para, M.F., Schouten, J., Rosenkranz, S.L., Yu, S., Weiner, D., Tebas, P., White, C.J., Reeds, D., Lertora, J., Patterson, K.B., Daar, E.S., Cavert, W., Brizz, B. J. Acquir. Immune Defic. Syndr. (2010)
- Qualitative and quantitative PCR measures of cytomegalovirus in patients with advanced HIV infection who require transfusions. Para, M.F., Kalish, L.A., Collier, A.C., Pollard, R.B., Kumar, P.N., Mintz, L., Wallach, F.R., Drew, W.L. J. Acquir. Immune Defic. Syndr. (2001)
- Correlates of change in cytomegalovirus viremia in patients with advanced human immunodeficiency virus infection who require transfusion. Para, M.F., Kalish, L.A., Collier, A.C., Murphy, E.L., Drew, W.L. J. Infect. Dis. (2001)
- Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333. Para, M.F., Glidden, D.V., Coombs, R.W., Collier, A.C., Condra, J.H., Craig, C., Bassett, R., Leavitt, R., Snyder, S., McAuliffe, V., Boucher, C. J. Infect. Dis. (2000)
- ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team. Para, M.F., Meehan, P., Holden-Wiltse, J., Fischl, M., Morse, G., Shafer, R., Demeter, L.M., Wood, K., Nevin, T., Virani-Ketter, N., Freimuth, W.W. Antimicrob. Agents Chemother. (1999)